Answers are grounded in this paper and cite their sources.
Patient subgroups defined by sex and BMI have different patterns of benefits and risks on thiazolidinedione and sulfonylurea therapy. Subgroup-specific estimates can inform discussion about the choice of therapy after metformin for an individual patient. Our approach using routine and shared trial data provides a framework for future stratification research in type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Dennis et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: